Stephanie Hsu, MD
Ophthalmology · Bellevue, WANPI 1811450315
Payments from drug & device makers
Across 35 payments — averaging $157.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Eyepoint US, Inc.$1K
- Apellis Pharmaceuticals, Inc.$822
- Regeneron$700
- Bausch & Lomb Americas Inc.$231
- Genentech, Inc.$197
- plus $586 from 7 others
What the payments were for
- Consulting fees$1,10020%
- Grants$70013%
- Travel & lodging$97918%
- Food & beverage$2,73650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 9 | $1,752 |
| Eyepoint US, Inc. | 3 | $1,227 |
| Apellis Pharmaceuticals, Inc. | 8 | $822 |
| Regeneron | 1 | $700 |
| Bausch & Lomb Americas Inc. | 2 | $231 |
| Genentech, Inc. | 2 | $197 |
| AbbVie | 2 | $159 |
| Stryker | 3 | $106 |
| Novartis | 1 | $106 |
| Glaukos Corporation | 1 | $98 |
| Biotissue Holdings Inc. | 1 | $58 |
| Astellas Pharma US Inc | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYP-1901$1,205
- Syfovre$574
- Constellation$244
- XIPERE$231
- VISUDYNE$231
- VABYSMO$136
- Hydrus Microstent$135
- RETISERT$121
- LUMIGAN$119
- XIIDRA$106
How this compares
$5,515 in reported general payments places this provider in the 80th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 217 | $8,470 |
| Atropine Sulfate | 85 | $2,210 |
| Ketorolac Tromethamine | 61 | $2,018 |
| Ofloxacin | 89 | $932 |
| ErythromycinErythromycin Base | 75 | $740 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $384 |
| Latanoprost | 14 | $184 |
| Timolol Maleate | 14 | $163 |
| Prednisone | 11 | $111 |
| Brimonidine Tartrate | 15 | $73 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Bellevue
- Todd KlesertBellevue$506K
- David SapersteinBellevue$235K
- Audrey RostovBellevue$220K
- Howard BarnebeyBellevue$62K
- Mary CodayBellevue$10K
- Robert WirthlinSpokane$2.4M
- Laura PerimanSeattle$1.9M
- Todd SchneidermanSilverdale$602K
- Sheldon CowenSeattle$560K
- Jason JonesSpokane$386K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.